1. Market Research
  2. > Pathology
Customer Support

Talk to Ahmad

+1 718 618 4302

Companies

  • All
    • Novartis AG
About 200 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Vaginal Cancer - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 381 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Sexually Transmitted Disease
  • United States
  • Novartis AG

NHL: Follicular lymphoma

  • $ 5000
  • April 2016
  • 252 pages

NHL: Follicular lymphoma Disease Coverage | Treatment: Follicular Lymphoma practices.

  • Healthcare
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Novartis AG

Pharmaceutical Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Route of Administration ; Application ; End User, and Geography

  • $ 4550
  • May 2020
  • 197 pages

Pfizer Inc. has received the European Commission (EC) for its Lorviqua for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced nonsmall cell lung cancer (NSCLC).

  • Lymphoma
  • Pharmaceutical
  • Forecast
  • Market Size
  • Novartis AG

Global Auto-Injectors Market (By Application/Indication, Product Type, Usability, Distribution Channels, Region), Key Company Profiles - Forecast to 2025

  • $ 1990
  • August 2019
  • 126 pages

lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD## therapies pursuant to its collaboration arrangements with Genentech, Inc.

  • Injectable Delivery
  • Lymphoma
  • World
  • Amgen Inc.
  • Novartis AG

Global Chemotherapy Drugs Market - Opportunities and Forecast (2013-2023)

  • $ 2200
  • March 2019
  • 200 pages

Lymphoma Gastrointestine Others Figure ##: Types of cancer for which clinical trials using chemotherapy drugs treatment are being conducted ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% Source: U. S Clinical Trials Registry GLOBAL THERAPEUTIC CHEMOTHERAPY DRUGS MARKET FIGURE ##: GLOBAL

  • Cancer
  • Chemotherapy
  • Lymphoma
  • Therapy
  • Novartis AG

T-Cell Immunotherapy Market (3rd Edition), 2018-2030

  • $ 3499
  • April 2018
  • 850 pages

LEUKEMIA AND LYMPHOMA ##. ##. ##. ##.

  • Immunotherapy
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Novartis AG

Cell & Gene Therapy Market - Global Outlook and Forecast 2020-2025

  • $ 3500
  • August 2020
  • 266 pages

IN MAY 2018, THE PRODUCT RECEIVED EXPANDED INDICATION APPROVAL FOR B-CELL LYMPHOMA.

  • Gene Therapy
  • Lymphoma
  • Therapy
  • World
  • Novartis AG

Vaginal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 351 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • United States
  • Novartis AG

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 403 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Novartis AG

Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • December 2019
  • 356 pages

IN ADDITION, THERE WERE SEVERAL CASES OF MALIGNANCY IN LEMTRADA-TREATED PATIENTS, INCLUDING NON-EBV-ASSOCIATED BURKITT LYMPHOMA, BREAST CANCER, AND CERVICAL CARCINOMA.

  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • United States
  • Novartis AG

Regenerative Medicine - Thematic Research

  • $ 1950
  • November 2019
  • 24 pages

Yescarta is a CAR-T therapy indicated for patients with certain types of B-cell lymphoma.

  • Lymphoma
  • Regenerative Medicine
  • DiscGenics, Inc.
  • Novartis AG
  • ViaCyte, Inc.

Global Regenerative Medicine Market - Opportunities and Forecast

  • $ 2400
  • August 2019
  • 326 pages

This strategic acquisition will further promote Gilead as an industry leader in refractory large B-cell lymphoma after two or more lines of therapy.

  • Biopharmaceutical
  • Lymphoma
  • Regenerative Medicine
  • Market Size
  • Novartis AG

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • April 2020
  • 204 pages

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028 Summary Age-related macular degeneration (AMD) is an eye condition that is characterized by the gradual deterioration ...

  • Lymphoma
  • Ophthalmology
  • Targeted Therapy
  • Therapy
  • Novartis AG

PharmSource - Cell Therapy Market Opportunity for CMOs - 2018 Edition

  • $ 4995
  • June 2018
  • 70 pages

Yescarta is also in Phase II investigation for mantle cell lymphoma and ALL.

  • Cell Therapy
  • Lymphoma
  • Medical Biotechnology
  • United States
  • Novartis AG

Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2029

  • $ 10995
  • June 2020
  • 139 pages

LYMPHOMAS GO-2032C GSK-## CHIMERIX INC EXCELLTHERA INC FUJIFILM HOLDINGS CORP FUJIFILM HOLDINGS CORP AVEO ONCOLOGY INC MACROGENICS INC SYNIMMUNE GMBH CHONGQING PRECISION BIOTECH CO LTD PERSONGEN BIOMEDICINE SUZHOU CO LTD PERSONGEN BIOMEDICINE SUZHOU CO LTD GENUS ONCOLOGY LLC GLAXOSMITH

  • Chemotherapy
  • Leukemia
  • Lymphoma
  • Therapy
  • Novartis AG

Global Orphan Drugs Market: Industry Analysis & Outlook (2018-2022)

  • $ 1000
  • July 2018
  • 79 pages

Celgene also gains full global rights to JCAR## (lisocabtagene maraleucel; liso-cel), a CD-## targeted CAR-T therapy currently in pivotal trials for relapsed and/ or refractory diffuse large B-cell lymphoma (DLBCL).

  • Lymphoma
  • Therapy
  • World
  • Bristol-Myers Squibb Company
  • Novartis AG

Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2027

  • $ 10995
  • December 2018
  • 106 pages

FURTHERMORE, PSORIASIS IS COMMONLY ASSOCIATED WITH NAIL DISEASE, CARDIOVASCULAR DISEASE (CVD), LYMPHOMA, AND INFLAMMATORY BOWEL DISEASE (IBD) (MENTER ET AL., 2009).

  • Dermatological Condition
  • Lymphoma
  • Pathology
  • Therapy
  • Novartis AG

Potential Pipeline Disruptors

  • $ 4200
  • May 2017
  • 120 pages

FOLLICULAR LYMPHOMA TENDS TO BE INDOLENT AND DIFFUSE LYMPHOMA TENDS TO BE AGGRESSIVE.

  • Lymphoma
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Novartis AG

Global CML Market Report - 2022

  • $ 3849
  • June 2018
  • 82 pages

Imatinib mesylate is licensed as a firstline treatment for adults with chronic-phase Ph+ CML, and for the management of GIST, and as salvage therapy for Ph+ acute lymphoblastic lymphoma.

  • Lymphoma
  • Therapy
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG

Liposome Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product ; Technology ; Application

  • $ 4550
  • April 2020
  • 177 pages

The liposome drug delivery market is expected to reach US$ 6,992.95 million by 2027 from US$ 3,594.41 million in 2019. The market is estimated to grow at a CAGR of 8.8% from 2020 to 2027. The growth of ...

  • Drug Delivery
  • Lymphoma
  • Topical Delivery
  • Forecast
  • Novartis AG
View report >

Hospital Forecast Statistics in the US

  • December 2017
  • 34 pages

GOV CHART ##: LYMPHOMA & NON-ACUTE LEUKEMIA W/ MAJOR COMPLICATIONS OR COMORBIDITIES CHART ##: LYMPHOMA & NON-ACUTE LEUKEMIA W/ MAJOR COMPLICATIONS OR COMORBIDITIES (CONTINUED) CHART ##: LYMPHOMA & NON-ACUTE LEUKEMIA W/ COMPLICATION OR COMORBIDITI

  • Hospital
  • Lymphoma
  • United States
  • Jefferies LLC
  • Novartis AG

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on